[
    {
        "id": "osp-12386",
        "type": "article-journal",
        "title": "Treatment outcome with interferon alpha 2b in ocular surface squamous neoplasia: Recommendation as primary treatment by peripheral ophthalmologists",
        "author": [
            {
                "family": "Meel",
                "given": "Rachna"
            },
            {
                "family": "Dhiman",
                "given": "Rebika"
            },
            {
                "family": "Vanathi",
                "given": "Murugesan"
            },
            {
                "family": "Sen",
                "given": "Seema"
            },
            {
                "family": "Gupta",
                "given": "Noopur"
            },
            {
                "family": "Tandon",
                "given": "Radhika"
            }
        ],
        "URL": "https://omanscience.com/en/articles/treatment-outcome-with-interferon-alpha-2b-in-ocular-surface-squamous-neoplasia-recommendation-as-primary-treatment-by-peripheral-ophthalmologists",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2021
                ]
            ]
        },
        "container-title": "Oman Journal of Ophthalmology",
        "volume": "14",
        "issue": "1",
        "page": "27-32",
        "DOI": "10.4103/ojo.ojo_201_2018",
        "publisher": "Medknow Publications",
        "ISSN": "0974-620X",
        "abstract": "Background: To evaluate the role of interferon alpha 2b (IFNα2b) in the management of primary/recurrent cases of ocular surface squamous neoplasia (OSSN).\n\nMethodology: Medical records of 27 OSSN cases managed with IFNα2b (topical drops and/or perilesional injection) in 1 year were retrospectively reviewed.\n\nResults: The median age of presentation was 60 years with a male: female ratio of 3.5:1. American Joint Commission on Cancer tumor grading was T1 in 1 eye (3.7%) and T3 in 26 eyes (96.3%). Eighteen cases were treated with topical drops (1 million IU/ml), 4 cases with perilesional subconjunctival injection (3-6 million IU/ml), and 5 cases with combined therapy. Overall, treatment response was seen in 88% cases. Complete regression was achieved in 80% cases. Median time to complete regression of tumor was 3 months (range 1-11 months) in cases treated with topical interferon therapy and 2.5 months (range 0.7-3 months) in cases managed with injections or a combination of the two. The mean duration of follow-up was 24 months. All cases with partial/no response showed complete regression on subsequent management with topical mitomycin C. None of the patients required surgery. Acute ocular surface congestion was seen in two patients necessitating discontinuation of therapy.\n\nConclusion: In view of excellent treatment outcome and few side-effects, interferons can be considered as a primary, safe, and cost-effective treatment option for OSSN not only in tertiary centers but also by peripheral ophthalmologists."
    }
]